Asset comparator
Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.
- Isracann Biosciences Inc.
- EssilorLuxottica
Comparative performance (base 100)
Each asset is worth 100 at October 13, 2025; a value of 120 means +20% since that date (latest common date: October 9, 2026).
Each performance is calculated in the asset's trading currency, without currency conversion.
Indicators
"Not applicable" indicates a metric that has no meaning for this type of asset: it should not be compared.
| Indicator | Isracann Biosciences Inc.Stock | EssilorLuxotticaStock |
|---|---|---|
| Performance and risk | ||
| Performance over the periodChange in price between the first and last common dates. | 0.0% | −46.7% |
| Annualized performanceAverage annual return that would produce the same total performance. | 0.0% | −47.1% |
| Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates. | 0.0% | 32.4% |
| Maximum DrawdownLargest decline from peak to subsequent trough over the period. | 0.0% | −56.7% |
| Sharpe RatioReturn achieved above the risk-free rate (5.24%), per unit of volatility. The higher it is, the better risk was rewarded over the period. | Indisponible | -1.54 |
| 1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR). | 0.0% | −3.6% |
| Fundamentals | ||
| Market capitalizationTotal market value of all shares (or circulating tokens for a crypto). | 1.76K $ | 66.99B € |
| P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid. | Indisponible | 27.3 |
| Price-to-SalesMarket capitalization divided by annual revenue. | Indisponible | 2.3 |
| Net marginShare of revenue retained as profit. | 0.0% | 8.5% |
| Return on equityReturn on equity (ROE). | −252.8% | 6.7% |
| Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year. | Indisponible | +5.7% |
| Dividend yieldAnnual dividend relative to the share price. | None | 2.80% |
| Debt / equityFinancial debt relative to shareholders' equity. | Indisponible | 38% |
Correlations over the period
From −1 to 1: close to 1, the two assets rise and fall together; close to 0, they move independently.
- Isracann Biosciences Inc. / EssilorLuxottica—
Information provided for educational purposes only. It does not constitute investment advice or a personalized recommendation. Past performance is no guarantee of future results.